AAAAAA
Results: 1-25/31
Authors:
LABELLE A
DEBEAUREPAIRE R
BOULAY LJ
NABER D
JONES BD
BARNES TRE
Citation: A. Labelle et al., A PILOT-STUDY OF THE SAFETY AND TOLERANCE OF SCH-39166 IN PATIENTS WITH SCHIZOPHRENIA, Journal of psychiatry & neuroscience, 23(2), 1998, pp. 93-94
Authors:
PAJONK FG
NABER D
Citation: Fg. Pajonk et D. Naber, HUMAN-IMMUNODEFICIENCY-VIRUS AND MENTAL-DISORDERS, Current opinion in psychiatry, 11(3), 1998, pp. 305-310
Authors:
NABER D
Citation: D. Naber, SUBJECTIVE EXPERIENCES OF SCHIZOPHRENIC-PATIENTS TREATED WITH ANTIPSYCHOTIC MEDICATION, International clinical psychopharmacology, 13, 1998, pp. 41-45
Authors:
FINCKH U
MANN U
MULLERTHOMSEN T
EGGERS C
NABER D
NITSCH RM
GAL A
Citation: U. Finckh et al., UNEXPECTED SPECTRUM OF DISEASE-CAUSING MUTATIONS IN A CLINICAL-SAMPLEOF PATIENTS WITH PRESENILE-DEMENTIA, American journal of medical genetics, 81(6), 1998, pp. 554-555
Authors:
GROWDON J
DENG A
THOMSEN TM
MANN U
BUHMANN J
STURENBURG HJ
EGGERS C
LANGER U
VELDEN J
VONDERKAMMER H
WIEGMANN H
KUNZE S
NABER D
REBECK B
SCHOENFELD D
HOCK C
NITSCH R
Citation: J. Growdon et al., CEREBROSPINAL-FLUID LEVELS OF A NOVEL PRESENILIN LOOP FRAGMENT ARE INCREASED IN ALZHEIMERS-DISEASE, Neurology, 50(4), 1998, pp. 33002-33002
Authors:
PETER H
STARK FM
LAUTERBACH B
NABER D
Citation: H. Peter et al., SYNERGISTIC EFFECTS BETWEEN BEHAVIOR-THERAPY AND SSRI TREATMENT - A CASE-REPORT OF A PATIENT WITH TREATMENT-RESISTANT DEPRESSION, Verhaltenstherapie, 7(4), 1997, pp. 235-242
Authors:
RIETSCHEL M
NABER D
FIMMERS R
MOLLER HJ
PROPPING P
NOTHEN MM
Citation: M. Rietschel et al., EFFICACY AND SIDE-EFFECTS OF CLOZAPINE NOT ASSOCIATED WITH VARIATION IN THE 5-HT2C RECEPTOR, NeuroReport, 8(8), 1997, pp. 1999-2003
Authors:
SOYKA M
BANZER K
BUCHBERGER R
VOLKL M
NABER D
Citation: M. Soyka et al., METHADONE-MAINTENANCE THERAPY IN OPIOID D EPENDENCE, Nervenheilkunde, 16(6), 1997, pp. 347-352
Authors:
RIETSCHEL M
KRAUSS H
FERNANDEZ ANY
MAIER W
NABER D
MOLLER HJ
PROPPING P
NOTHEN MM
Citation: M. Rietschel et al., WEIGHT-GAIN AND EEG ALTERATIONS UNDER TREATMENT WITH CLOZAPINE NOT ASSOCIATED WITH 5-HT2C VARIANTS, American journal of medical genetics, 74(6), 1997, pp. 617-617
Authors:
NABER D
KIRCHER T
HESSEL K
Citation: D. Naber et al., SCHIZOPHRENIC-PATIENTS RETROSPECTIVE ATTITUDES REGARDING INVOLUNTARY PSYCHOPHARMACOLOGICAL TREATMENT AND RESTRAINT, European psychiatry, 11(1), 1996, pp. 7-11
Authors:
LABELLE A
DEBEAUREPAIRE R
BOULAY LJ
JONES BD
NABER D
BARNES TRE
Citation: A. Labelle et al., EFFICACY, SAFETY AND TOLERANCE OF A D-1 ANTAGONIST SCH-3966 IN 6 CASES OF ACUTE PSYCHOTIC STATES, Schizophrenia research, 18(2-3), 1996, pp. 4-4
Authors:
RIETSCHEL M
NABER D
OBERLANDER H
HOLZBACH R
FIMMERS R
EGGERMANN K
MOLLER HJ
PROPPING P
NOTHEN MM
Citation: M. Rietschel et al., EFFICACY AND SIDE-EFFECTS OF CLOZAPINE - TESTING FOR ASSOCIATION WITHALLELIC VARIATION IN THE DOPAMINE D-4 RECEPTOR GENE, Neuropsychopharmacology, 15(5), 1996, pp. 491-496
Authors:
NABER D
SAND P
HEIGL B
Citation: D. Naber et al., PSYCHOPATHOLOGICAL AND NEUROPSYCHOLOGICAL EFFECTS OF 8-DAYS CORTICOSTEROID TREATMENT - A PROSPECTIVE-STUDY, Psychoneuroendocrinology, 21(1), 1996, pp. 25-31
Authors:
MODELL S
NABER D
HOLZBACH R
Citation: S. Modell et al., EFFICACY AND SAFETY OF AN OPIATE SIGMA-RECEPTOR ANTAGONIST (SL-82.0715) IN SCHIZOPHRENIC-PATIENTS WITH NEGATIVE SYMPTOMS - AN OPEN DOSE-RANGE STUDY, Pharmacopsychiatry, 29(2), 1996, pp. 63-66
Authors:
SOYKA M
HOLLWEG M
NABER D
Citation: M. Soyka et al., ALCOHOL DEPENDENCE AND DEPRESSION - CLASS IFICATION, COMORBIDITY, GENETIC AND NEUROBIOLOGICAL ASPECTS, Nervenarzt, 67(11), 1996, pp. 896-904
Authors:
DEBEAUREPAIRE R
LABELLE A
NABER D
JONES BD
BARNES TRE
Citation: R. Debeaurepaire et al., AN OPEN TRIAL OF THE D-1 ANTAGONIST SCH-39166 IN 6 CASES OF ACUTE PSYCHOTIC STATES, Psychopharmacology, 121(3), 1995, pp. 323-327
Authors:
NABER D
Citation: D. Naber, A SELF-RATING TO MEASURE SUBJECTIVE EFFECTS OF NEUROLEPTIC DRUGS, RELATIONSHIPS TO OBJECTIVE PSYCHOPATHOLOGY, QUALITY-OF-LIFE, COMPLIANCE AND OTHER CLINICAL-VARIABLES, International clinical psychopharmacology, 10, 1995, pp. 133-138
Authors:
NOTHEN MM
RIETSCHEL M
ERDMANN J
OBERLANDER H
MOLLER HJ
NABER D
PROPPING P
Citation: Mm. Nothen et al., GENETIC-VARIATION OF THE 5-HT2A RECEPTOR AND RESPONSE TO CLOZAPINE, Lancet, 346(8979), 1995, pp. 908-909
Authors:
ZARATE CA
DANIEL DG
KINON BJ
LITMAN RE
NABER D
PICKAR D
SATO M
Citation: Ca. Zarate et al., INTERNATIONAL PSYCHOPHARMACOLOGY ALGORITHM PROJECT REPORT .A. ALGORITHMS FOR THE TREATMENT OF SCHIZOPHRENIA, Psychopharmacology bulletin, 31(3), 1995, pp. 461-467
Authors:
NIEDERECKER M
NABER D
RIEDEL R
PERRO C
GOEBEL FD
Citation: M. Niederecker et al., FREQUENCY AND ETIOLOGY OF PSYCHOSES IN HI V-INFECTED PATIENTS, Nervenarzt, 66(5), 1995, pp. 367-371
Authors:
KATHMANN N
KUISLE U
BOMMER M
NABER D
MULLER OA
ENGEL RR
Citation: N. Kathmann et al., EFFECTS OF ELEVATED TRIIODOTHYRONINE ON COGNITIVE PERFORMANCE AND MOOD IN HEALTHY-SUBJECTS, Neuropsychobiology, 29(3), 1994, pp. 136-142
Authors:
NABER D
Citation: D. Naber, TREATMENT OF DRUG-ADDICTS AT A GENERAL-HO SPITAL, Der Internist, 35(9), 1994, pp. 858-862
Authors:
MAJ M
SATZ P
JANSSEN R
ZAUDIG M
STARACE F
DELIA L
SUGHONDHABIROM B
MUSSA M
NABER D
NDETEI D
SCHULTE G
SARTORIUS N
Citation: M. Maj et al., WHO NEUROPSYCHIATRIC AIDS STUDY, CROSS-SECTIONAL PHASE-II - NEUROPSYCHOLOGICAL AND NEUROLOGICAL FINDINGS, Archives of general psychiatry, 51(1), 1994, pp. 51-61
Authors:
NABER D
PAJONK FG
PERRO C
LOHMER B
Citation: D. Naber et al., HUMAN-IMMUNODEFICIENCY-VIRUS ANTIBODY-TEST AND SEROPREVALENCE IN PSYCHIATRIC-PATIENTS, Acta psychiatrica Scandinavica, 89(5), 1994, pp. 358-361
Authors:
PERRO C
GEIER SA
NABER D
KLAUSS V
KRONAWITTER U
BOGNER JR
GOEBEL ED
Citation: C. Perro et al., HIV-RELATED OCULAR MICROANGIOPATHIC SYNDROME AND NEUROPSYCHOLOGICAL FUNCTIONING, AIDS, 7(4), 1993, pp. 595-596